Responsive nanomedicines enhanced by or enhancing physical modalities to treat solid cancer tumors: Preclinical and clinical evidence of safety and efficacy

Adv Drug Deliv Rev. 2022 Feb:181:114075. doi: 10.1016/j.addr.2021.114075. Epub 2021 Dec 6.

Abstract

Nanomedicine has improved cancer treatment but not to the extent anticipated. Responsive nanomedicines enhanced by physical modalities (radiation, ultrasounds, alternating magnetic fields) or enhancing the activity of physical modalities such as radiotherapy to kill cancer represents an important approach in improving the safety and anticancer effectiveness. Importantly, the combined treatments have shown promise for the treatment of difficult to treat tumors, such as tumors that are resistant to chemotherapy (multi drug resistant, MDR) or radiotherapy and hypoxic tumors, and for the prevention of tumor metastasis. In this review, the mechanisms of responsive nanomedicines activity enhancement by physical means and vice versa are presented and preclinical and, most importantly, clinical evidence of the safety and efficacy of nanomedicines enhanced by or enhancing by physical modalities in treating solid tumors are critically discussed.

Keywords: AFM; Cancer; Focused ultrasounds; Nanomedicines; Photodynamic therapy; Photothermal ablation; Radiotherapy.

Publication types

  • Review

MeSH terms

  • Antineoplastic Agents / administration & dosage
  • Combined Modality Therapy
  • Drug Delivery Systems / methods*
  • Extracorporeal Shockwave Therapy / methods*
  • Humans
  • Nanoparticle Drug Delivery System*
  • Neoplasms / drug therapy
  • Neoplasms / therapy*
  • Photothermal Therapy / methods*
  • Radiotherapy / methods*
  • Reactive Oxygen Species

Substances

  • Antineoplastic Agents
  • Nanoparticle Drug Delivery System
  • Reactive Oxygen Species